Advanced in Hairy Cell Leukemia (HCL)

Dr. Joseph M. Tuscano

Hematology Oncology | Hematology | Oncology
Regents Of The Univ Of Ca
4501 X St, 
Sacramento, CA 
Offers Telehealth
Advanced in Hairy Cell Leukemia (HCL)
Regents Of The Univ Of Ca
4501 X St, 
Sacramento, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joseph Tuscano is a Hematologist Oncology specialist and a Hematologist in Sacramento, California. Dr. Tuscano is rated as an Advanced provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 84 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 1 clinical trial in the study of Hairy Cell Leukemia (HCL).

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
University Of California Davis Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Health Advantage
  • HMO
  • INSURANCE PLAN
  • MEDICARE DISCOUNT CARD
  • MEDICARE MAPD
View 6 Less Insurance Carriers -

Locations

REGENTS OF THE UNIV OF CA
4501 X St, Sacramento, CA 95817

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination With Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma
A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination With Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Biological, Drug
Study Drugs: Atezolizumab, Gemcitabine, Oxaliplatin, Rituximab
Study Phase: Phase 1
A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Biological, Procedure, Other
Study Drugs: Nivolumab, Talimogene Laherparevec
Study Phase: Phase 2
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2025
Intervention Type: Drug, Other
Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide
Study Phase: Phase 3
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
Enrollment Status: Active_not_recruiting
Publish Date: June 29, 2025
Intervention Type: Other, Biological
Study Drug: MEDI-570
Study Phase: Phase 1
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2025
Intervention Type: Biological, Drug
Study Drugs: Blinatumomab, Lenalidomide
Study Phase: Phase 1
A Phase I/IB Pilot Study of CC-486 Combined With Lenalidomide and Obinutuzumab for Relapsed/Refractory Indolent B-Cell Lymphoma
A Phase I/IB Pilot Study of CC-486 Combined With Lenalidomide and Obinutuzumab for Relapsed/Refractory Indolent B-Cell Lymphoma
Enrollment Status: Completed
Publish Date: April 24, 2025
Intervention Type: Biological, Drug
Study Drugs: Lenalidomide, Obinutuzumab, Azacitidine
Study Phase: Phase 1
A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Enrollment Status: Completed
Publish Date: February 12, 2025
Intervention Type: Drug
Study Drugs: Cirmtuzumab, Ibrutinib
Study Phase: Phase 1/Phase 2
Phase I/II Study of Ixazomib in Combination with Pomalidomide, Clarithromycin and Dexamethasone (PiC-D) in Patients with Double Refractory Multiple Myeloma
Phase I/II Study of Ixazomib in Combination with Pomalidomide, Clarithromycin and Dexamethasone (PiC-D) in Patients with Double Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Clarithromycin, Dexamethasone, Ixazomib Citrate, Pomalidomide
Study Phase: Phase 1/Phase 2
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drug: STRO-001
Study Phase: Phase 1
A Phase I and Randomized Phase II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed, Refractory Diffuse Large-B Cell Lymphoma
A Phase I and Randomized Phase II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed, Refractory Diffuse Large-B Cell Lymphoma
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Biological
Study Drugs: Mogamulizumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
Use of Zevalin to Enhance the Efficacy of Non-Myeloablative Allogeneic Transplantation in Patients With Relapsed or Refractory CD20+ Non-Hodgkin's Lymphoma
Use of Zevalin to Enhance the Efficacy of Non-Myeloablative Allogeneic Transplantation in Patients With Relapsed or Refractory CD20+ Non-Hodgkin's Lymphoma
Enrollment Status: Unknown
Publish Date: November 30, 2022
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Rituximab, Ibritumomab tiuxetan, Anti-thymocyte globulin, Cyclosporine, Mycophenolate mofetil
Study Phase: Phase 2
Phase II Trial of the Combination of Subcutaneous (SQ) Bortezomib and Pegylated Liposomal Doxorubicin (PLD or Doxil or LipoDox) for the Treatment of Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML)
Phase II Trial of the Combination of Subcutaneous (SQ) Bortezomib and Pegylated Liposomal Doxorubicin (PLD or Doxil or LipoDox) for the Treatment of Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML)
Enrollment Status: Completed
Publish Date: February 24, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 14 Less Clinical Trials

84 Total Publications

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.
NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: October 09, 2025
Similar Doctors
Distinguished in Hairy Cell Leukemia (HCL)
Dr. Dyaneshbapu G. Ravindran
Hematology Oncology | Oncology
Distinguished in Hairy Cell Leukemia (HCL)
Dr. Dyaneshbapu G. Ravindran
Hematology Oncology | Oncology
100 Hospital Drive, Suite 110, 
Vallejo, CA 
 (51.7 miles away)
707-551-3300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dyaneshbapu Ravindran is a Hematologist Oncology specialist and an Oncologist in Vallejo, California. Dr. Ravindran is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Paget Disease of the Breast, Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), and Richter Syndrome. Dr. Ravindran is currently accepting new patients.

Prathima Prodduturi
Distinguished in Hairy Cell Leukemia (HCL)
Dr. Prathima Prodduturi
Hematology
Distinguished in Hairy Cell Leukemia (HCL)
Dr. Prathima Prodduturi
Hematology
11720 Education St., Suite 1, 
Auburn, CA 
 (32.9 miles away)
530-889-6090
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Prathima Prodduturi is a Hematologist in Auburn, California. Dr. Prodduturi is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). Her top areas of expertise are Reticuloendotheliosis, Hairy Cell Leukemia (HCL), B-Cell Lymphoma, and Idiopathic Pulmonary Hemosiderosis. Dr. Prodduturi is currently accepting new patients.

Vijay Suhag
Distinguished in Hairy Cell Leukemia (HCL)
Dr. Vijay Suhag
Hematology
Distinguished in Hairy Cell Leukemia (HCL)
Dr. Vijay Suhag
Hematology

8 Medical Plaza Care Center

8 Medical Plaza Drive, Suite 300, 
Roseville, CA 
 (18.3 miles away)
916-782-5106
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vijay Suhag is a Hematologist in Roseville, California. Dr. Suhag is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Hairy Cell Leukemia (HCL), Anemia, and Gastric Lymphoma. Dr. Suhag is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tuscano's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 23 Advanced Conditions
View All 36 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile